Minerva Neurosciences Business Summary

Minerva Neurosciences, Inc. (NERV) is a clinical-stage biopharmaceutical company operating under a research and development business model focused on the treatment of central nervous system (CNS) disorders. The company currently generates no product revenue, sustaining operations through equity financing, private placements, and strategic partnerships, such as its royalty agreement with Royalty Pharma and its collaboration with Janssen Pharmaceutica for seltorexant. Its primary business segment is drug development, centered on its lead candidate, roluperidone (MIN-101), which targets the negative symptoms of schizophrenia—a significant unmet medical need. Minerva competes directly with major CNS players like Intra-Cellular Therapies, Acadia Pharmaceuticals, and Bristol Myers Squibb (following its acquisition of Karuna Therapeutics), positioning itself as a niche specialist focusing on symptom domains that traditional dopaminergic antipsychotics fail to address. The leadership team is anchored by Executive Chairman and CEO Dr. Remy Luthringer, a neuroscientist with a pedigree involving the development of over 150 CNS molecules and a background as an advisor to Medicxi Ventures. He is supported by President Geoff Race, a co-founder with extensive experience in biotech exits (Funxional Therapeutics and PanGenetics), and CFO Frederick Ahlholm, who oversees the company’s complex capital requirements. In late 2025, the company strengthened its clinical oversight by appointing Dr. Inderjit Kaul, a key figure in the development of the schizophrenia drug Cobenfy, to its Board of Directors. Minerva is backed by high-profile institutional investors including Vivo Capital, which led a $200 million financing round in October 2025, alongside Federated Hermes, Janus Henderson Investors, and Farallon Capital Management.